FULC — Fulcrum Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1680581 ·
Last close
$3.75
Market Cap
$286.11M
52W High
$15.74
52W Low
$2.83
ADV30
1,427,929
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -19,906,000 | -26,179,000 | 323,952,000 | 48,466,000 | 13,255,000 |
| Mar 2026 | 0 | — | -22,186,000 | -18,891,000 | 346,770,000 | 50,261,000 | 13,467,000 |
| Dec 2025 | 0 | — | -22,693,000 | -20,334,000 | 366,284,000 | 197,533,000 | 17,284,000 |
| Sep 2025 | 0 | — | -21,858,000 | -19,595,000 | 214,858,000 | 47,078,000 | 16,492,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-65,777,000
Investing CF
$-96,868,000
Financing CF
$168,410,000
CapEx
$-365,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.21
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-639,348,000
Inventory
—
Receivables
$2,030,000
ST Investments
$270,374,000
EBIT TTM
$-86,643,000
Pretax Income TTM
$-84,999,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,769,000 | -74,880,000 | 366,284,000 | 17,284,000 | 349,000,000 | -60,065,000 |
| Dec 2024 | 80,000,000 | -19,834,000 | -9,725,000 | 260,718,000 | 17,684,000 | 243,034,000 | -2,218,000 |
| Dec 2023 | 2,805,000 | -110,664,000 | -97,335,000 | 257,694,000 | 22,501,000 | 235,193,000 | -90,965,000 |
| Dec 2022 | 6,342,000 | -112,134,000 | -109,871,000 | 226,685,000 | 27,743,000 | 198,942,000 | -97,050,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-76,116,000
OpCashFlow TTM
—
Assets (Latest)
$346,770,000
Forward EPS
$-0.49
Max Pain — expiry 2026-12-18
max pain strike: $4.00 · spot: $3.75 · call oi: 4,376 · put oi: 349
Expected Move to 2026-12-18:
±$0.36
(9.60%) —
implied range
$3.39 –
$4.11
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $285.44M | $0.26 | — |
| BIOA | BioAge Labs, Inc. | $285.02M | $6.21 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $283.63M | $4.96 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $288.71M | $2.63 | — |
| LRMR | Larimar Therapeutics, Inc. | $280.48M | $2.70 | — |
News headlines (Yahoo Finance, 1h cache)
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
2026-08-25 18:28 · Yahoo
Fulcrum and Slate Medicines sign merger agreement
2026-08-18 08:56 · Yahoo
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies
2026-08-17 16:11 · Yahoo
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
2026-08-17 13:02 · Yahoo
Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger
2026-08-17 11:52 · Yahoo
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
2026-08-17 11:00 · Yahoo
Slate, Fulcrum to combine in reverse merger
2026-08-17 10:23 · Yahoo
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit
2026-06-27 20:06 · Yahoo
A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs
2026-06-11 19:53 · Yahoo
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring
2026-06-05 15:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.